BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cell & Gene

Bristol Myers Squibb’s Breyanzi Recommended for EU Approval After 97% Response Rate in Follicular Lymphoma

Recommendation based on the Phase 2 TRANSCEND FL study in which 97.1% of patients responded to Breyanzi, with 94.2% of patients achieving comple...

February 03, 2025 | News

VectorBuilder’s Partner Ucello Secures FDA IND Approval for UC101, the World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Therapy

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investi...

January 30, 2025 | News

CPC Introduces MicroCNX® Nano Series Connectors to Streamline Cell and Gene Therapy Processing

CPC (Colder Products Company), part of Dover (NYSE: DOV) and a leading manufacturer of connection technologies used in biopharmaceutic...

January 30, 2025 | News

GC Cell Hosts Landmark Symposium in Indonesia to Spotlight Immuncell-LC Cancer Immunotherapy

GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia....

January 24, 2025 | News

CARsgen Therapeutics Administers First Dose of KJ-C2320 Allogeneic CAR T-Cell Therapy in Investigator-Initiated Trial

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

January 21, 2025 | News

YolTech Therapeutics Launches Clinical Trial for YOLT-204 a First-in-Class Gene Editing Therapy for Beta-Thalassemia

YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for Y...

January 21, 2025 | News

Charles River and Akron Bio Advance Cell Therapy Manufacturing with Integration of Closed System Cytokines

Charles River Laboratories International, Inc. (NYSE: CRL) and Akron Bio (“Akron”), a leading supplier of critical materials and services for a...

January 17, 2025 | News

Verismo Therapeutics Secures $4.05M Investment from IFLI to Advance SynKIR™-310 for Follicular Lymphoma

Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with...

January 08, 2025 | News

JCR Pharmaceuticals and Modalis Therapeutics Advance CNS Gene Therapy Collaboration

JCR Pharmaceuticals Co., Ltd. and Modalis Therapeutics Corporation announced that they have validated the initial proof of concept in a jo...

January 06, 2025 | News

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy After Pfizer Ends Collaboration

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it will regain development and commercialization rights to giroctoco...

January 02, 2025 | News

Sensorion Completes Enrollment for First Cohort in Audiogene Phase 1/2 Gene Therapy Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to re...

January 01, 2025 | News

CARsgen Launches Clinical Trial in China for Innovative Allogeneic CAR T Therapy Targeting CD19/CD20

CARsgen Therapeutics Holdings Limited , a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...

January 01, 2025 | News

CARsgen's Satricabtagene Autoleucel Achieves Positive Phase II Results in Advanced Gastric Cancer

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic mal...

December 31, 2024 | News

I Peace Achieves Milestone of Manufacturing 100 GMP-Grade iPS Cell Lines

Leading GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the n...

December 31, 2024 | News

Stay Connected